Source:http://linkedlifedata.com/resource/pubmed/id/16189183
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2005-9-28
|
| pubmed:abstractText |
About 50-64% of human breast cancers express receptors for GnRH-I. Direct antiproliferative effects of analogs of GnRH-I on human breast cancer cell lines have been shown. They are at least in part mediated by antagonizing growth promoting effects of estradiol, epidermal growth factor (EGF) or insulin-like growth factor. Recently, expression of a putative receptor for GnRH-II in human tissues was demonstrated. Antiproliferative effects of GnRH-II in human endometrial and ovarian cancer cells were shown not to be mediated through the GnRH-I receptor. Now we demonstrate direct anti-proliferative effects of the GnRH-I analog Triptorelin and the GnRH-II analog [d-Lys(6)]GnRH-II in MCF-7 and T47D human breast cancer cells expressing GnRH-I receptors and putative GnRH-II receptors. Pretreatment with Triptorelin or [d-Lys(6)]GnRH-II blocked EGF-induced autophosphoryla-tion of EGF receptor and activation of mitogen-activated protein kinase (extracellular-signal-regulated kinase 1/2 (ERK1/2)) in these cells. In sublines of MCF-7 and T47D cells, which were developed to be resistant to 4OH-tamoxifen, HER-2/p185 was overexpressed. Pretreatment of these cell lines with Triptorelin or [d-Lys(6)]GnRH-II completely abolished resistance to 4OH-tamoxifen, assessed by 4OH-tamoxifen-induced apoptosis. Analogs of GnRH-I and GnRH-II counteract EGF-dependent signal transduction in human breast cancer cells with expression of receptors for GnRH-I and GnRH-II. Through this mechanism, they probably reverse acquired resistance to 4OH-tamoxifen mediated through overexpression or activation of receptors of the c-erbB family.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/4-hydroxytamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Signal-Regulated MAP...,
http://linkedlifedata.com/resource/pubmed/chemical/Gonadotropin-Releasing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Triptorelin Pamoate,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0804-4643
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
153
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
613-25
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:16189183-Antineoplastic Agents,
pubmed-meshheading:16189183-Apoptosis,
pubmed-meshheading:16189183-Breast Neoplasms,
pubmed-meshheading:16189183-Cell Line, Tumor,
pubmed-meshheading:16189183-Cell Proliferation,
pubmed-meshheading:16189183-Drug Resistance, Neoplasm,
pubmed-meshheading:16189183-Enzyme Activation,
pubmed-meshheading:16189183-Epidermal Growth Factor,
pubmed-meshheading:16189183-Estrogen Antagonists,
pubmed-meshheading:16189183-Extracellular Signal-Regulated MAP Kinases,
pubmed-meshheading:16189183-Female,
pubmed-meshheading:16189183-Gonadotropin-Releasing Hormone,
pubmed-meshheading:16189183-Humans,
pubmed-meshheading:16189183-Phosphorylation,
pubmed-meshheading:16189183-Quinazolines,
pubmed-meshheading:16189183-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16189183-Signal Transduction,
pubmed-meshheading:16189183-Tamoxifen,
pubmed-meshheading:16189183-Triptorelin Pamoate
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
|
| pubmed:affiliation |
Department of Gynecology and Obstetrics, Georg-August-University, Robert-Koch-Street 40, D-37075 Göttingen, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|